Neutropenic Mouse Thigh Model Now Offered by ImQuest BioSciences
October 7, 2013
Frederick, MD; October 7, 2013 - ImQuest BioSciences (Frederick, MD), in collaboration with Noble Life Sciences (Gaithersburg, MD), has successfully developed a neutropenic mouse thigh model of infection and demonstrated its use in a study evaluating vancomycin for the treatment of Staphylococcus aureus infection. The model will serve as a new service for the evaluation of the efficacy of novel anti-microbial compounds in the treatment of microbial infections.
Complicated skin and soft tissue infections are frequently encountered in clinical practice and are a significant cause of morbidity and mortality in hospitalized patients. The neutropenic mouse thigh model of infection has been used extensively to test and benchmark antimicrobial drugs leading to a significant impact on our current knowledge of antimicrobial pharmacology. This model allows the quantitative comparison of different agents and different dosing regimes and the determination of the time-course of antimicrobial activity under conditions optimal for efficacy, i.e., neutropenia.
Robert Buckheit, Jr. PhD, President and CSO of ImQuest BioSciences, noted, "The optimization of this model is the result of a collaborative effort combining the microbiology expertise of ImQuest BioSciences with the animal model and drug development expertise of Noble Life Sciences."
"We are pleased with our collaboration with Noble Life Sciences in the optimization of this model. The model should be of particular interest to companies developing antimicrobial drugs that will expand the choices available to physicians facing increasing antimicrobial resistance," commented Dr. Buckheit.
About ImQuest BioSciences
ImQuest BioSciences, is a contract research organization (CRO) focused on the development of agents for the prevention and treatment of infectious disease and cancer, as well as specialized capabilities to support the pre-formulation and formulation development for optimal product delivery. ImQuest’s proprietary SUCCESS platform enables the rapid identification of drug candidates with a high probability of clinical success thereby reducing the risk associated with failure during clinical trials. The platform can be used for the identification of antiviral agents, antimicrobial drugs including topical microbicides, and oncology drugs. For more information about ImQuest BioSciences, visit: www.imquestbio.com.
About Noble Life Sciences
Noble Life Sciences provides in vitro and in vivo preclinical drug development services including experimental design and testing, animal and cellular disease models, cell line development and protein production, selection and validation of biomarkers, and vivarium services. With deep expertise in drug development, the company offers access to their top scientists who work collaboratively with researchers to expedite preclinical and clinical therapeutic development. For more information about Noble Life Sciences, visit www.noblelifesci.com.
Return to Press Releases